Literature DB >> 32356314

MiR-129-5p induces cell cycle arrest through modulating HOXC10/Cyclin D1 to inhibit gastric cancer progression.

Jiamin He1,2, Qiwei Ge2,3, Zhenghua Lin2,3, Weiyi Shen1,2, Renbin Lin1,2, Jiaguo Wu1,2, Boya Wang2,4, Yunkun Lu5, Luyi Chen1,2, Xiaosun Liu6, Wenfang Zheng1,2, Ying Zhang1,2, Lan Wang1,2, Kan Wang1,2, Liangjing Wang2,3, Wei Zhuo2,5, Shujie Chen1,2.   

Abstract

MicroRNAs (miRNAs) play important roles in posttranscriptional regulation and may serve as targets for the diagnosis and treatment of cancers. Nevertheless, a comprehensive understanding of miRNAs profiles in gastric cancer progression is still lacking. Here, we report that miR-129-5p is downregulated in gastric cancer by analyzing TCGA database (n = 41) and clinical tumor samples (n = 60). MiR-129-5p transfection suppressed gastric cancer cell proliferation through inducing G1 phase arrest in vitro and inhibit xenograft tumor growth in vivo. MiR-129-5p directly targeted the 3' untranslated regions (3' UTR) of HOXC10 mRNA and downregulated its expression. Importantly, miR-129-5p could reverse the oncogenic effect induced by HOXC10. We systemically screened the downstream target of HOXC10 by ChIP sequencing, and found that HOXC10 could transcriptionally regulate the expression of Cyclin D1 and facilitate G1/S cell cycle transition. Notably, high levels of HOXC10 and Cyclin D1 were related with poor prognosis of gastric cancer patients (n = 90). These findings reveal a novel role of miR-129-5p/HOXC10/Cyclin D1 axis in modulating cell cycle and gastric tumorigenesis, which might provide potential prognostic biomarkers and therapeutic targets for gastric cancer patients.
© 2020 Federation of American Societies for Experimental Biology.

Entities:  

Keywords:  HOXC10; cell cycle; cyclin D1; gastric cancer; miR-129-5p

Year:  2020        PMID: 32356314     DOI: 10.1096/fj.201903217R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  7 in total

1.  Long Non-Coding RNA KCNQ1OT1 Promotes Progression of Hepatocellular Carcinoma by miR-148a-3p/IGF1R Axis.

Authors:  Guoping Xu; Yungang Zhu; Huijia Liu; Yingying Liu; Xuening Zhang
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

Review 2.  The Role of Non-Coding RNAs in Controlling Cell Cycle Related Proteins in Cancer Cells.

Authors:  Soudeh Ghafouri-Fard; Hamed Shoorei; Farhad Tondro Anamag; Mohammad Taheri
Journal:  Front Oncol       Date:  2020-11-30       Impact factor: 6.244

3.  HOXC10 promotes growth and migration of melanoma by regulating Slug to activate the YAP/TAZ signaling pathway.

Authors:  Yuanxin Miao; Weina Zhang; Su Liu; Xiangfeng Leng; Chunnan Hu; Hao Sun
Journal:  Discov Oncol       Date:  2021-04-26

4.  Fusobacterium nucleatum promotes colorectal cancer cells adhesion to endothelial cells and facilitates extravasation and metastasis by inducing ALPK1/NF-κB/ICAM1 axis.

Authors:  Ying Zhang; Lu Zhang; Sheng Zheng; Mengjie Li; Chaochao Xu; Dingjiacheng Jia; Yadong Qi; Tongyao Hou; Lan Wang; Boya Wang; Aiqing Li; Shujie Chen; Jianmin Si; Wei Zhuo
Journal:  Gut Microbes       Date:  2022 Jan-Dec

5.  Circular RNA coiled-coil domain containing 66 regulates malignant development of papillary thyroid carcinoma by upregulating La ribonucleoprotein 1 via the sponge effect on miR-129-5p.

Authors:  Peipei Li; Junhui Chen; Jun Zou; Wei Zhu; Yan Zang; Hongwu Li
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

Review 6.  Downstream of the HOX genes: Explaining conflicting tumour suppressor and oncogenic functions in cancer.

Authors:  Richard Morgan; Keith Hunter; Hardev S Pandha
Journal:  Int J Cancer       Date:  2022-02-15       Impact factor: 7.316

7.  miR-149 Suppresses the Proliferation and Metastasis of Human Gastric Cancer Cells by Targeting FOXC1.

Authors:  Dan Li; Yunqing Zhang; Yulong Li; Xiaofei Wang; Fenghui Wang; Juan Du; Huahua Zhang; Haiyan Shi; Yanfeng Wang; Yi Gao; Yun Feng; Jing Yan; Yajuan Xue; Yang Yang; Jing Zhang
Journal:  Biomed Res Int       Date:  2021-12-17       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.